Trial Profile
CAnadian Normoglycemia Outcomes Evaluation Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Rosiglitazone/metformin (Primary)
- Indications Glucose intolerance; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CANOE
- 23 May 2012 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 03 Jun 2010 Primary endpoint 'Disease occurrence rate' has been met according to results published in the Lancet.